{"id":"isatuximab-iv","safety":{"commonSideEffects":[{"rate":"approximately 40-50%","effect":"Infusion-related reactions"},{"rate":"approximately 30-40%","effect":"Neutropenia"},{"rate":"approximately 20-30%","effect":"Anemia"},{"rate":"approximately 15-25%","effect":"Thrombocytopenia"},{"rate":"approximately 20-30%","effect":"Fatigue"},{"rate":"approximately 10-15%","effect":"Pneumonia"},{"rate":"approximately 10-15%","effect":"Upper respiratory tract infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Isatuximab targets CD38, a surface antigen highly expressed on multiple myeloma cells. By binding to CD38, it activates antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC), leading to direct tumor cell death. It also modulates the immunosuppressive tumor microenvironment by reducing CD38+ regulatory T cells and myeloid-derived suppressor cells.","oneSentence":"Isatuximab is a monoclonal antibody that binds to CD38 on the surface of multiple myeloma cells, triggering their destruction through multiple immune mechanisms.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:17:16.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple myeloma (in combination with pomalidomide and dexamethasone)"},{"name":"Multiple myeloma (in combination with carfilzomib and dexamethasone)"}]},"trialDetails":[{"nctId":"NCT04835129","phase":"PHASE2","title":"Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2022-01-10","conditions":"Multiple Myeloma","enrollment":28},{"nctId":"NCT07479979","phase":"PHASE1, PHASE2","title":"Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Natalie Callander","startDate":"2026-07","conditions":"Relapse Multiple Myeloma, Refractory Multiple Myeloma","enrollment":62},{"nctId":"NCT05690984","phase":"PHASE2","title":"Elimination of Minimal Residual Disease After Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-06-26","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT04883242","phase":"PHASE2","title":"Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2021-07-29","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":30},{"nctId":"NCT06203912","phase":"PHASE1","title":"Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Elvira Umyarova","startDate":"2024-03-05","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":3},{"nctId":"NCT06356571","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-03-17","conditions":"Plasma Cell Myeloma Refractory","enrollment":64},{"nctId":"NCT05344833","phase":"PHASE2","title":"Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2023-01-05","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT05804032","phase":"PHASE3","title":"Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma","status":"COMPLETED","sponsor":"University of Heidelberg Medical Center","startDate":"2023-04-14","conditions":"Multiple Myeloma","enrollment":514},{"nctId":"NCT04754945","phase":"PHASE1","title":"Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2021-04-28","conditions":"AL Amyloidosis","enrollment":11},{"nctId":"NCT06860269","phase":"PHASE2, PHASE3","title":"A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-05-06","conditions":"Acute Lymphoblastic Leukemia","enrollment":1200},{"nctId":"NCT04751877","phase":"PHASE3","title":"Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2021-07-17","conditions":"Multiple Myeloma, Myeloma","enrollment":270},{"nctId":"NCT04430894","phase":"PHASE2","title":"KRDI in Transplant-Eligible MM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-10","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT04240054","phase":"PHASE2","title":"Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-11-02","conditions":"Multiple Myeloma","enrollment":41},{"nctId":"NCT05137054","phase":"PHASE1","title":"A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2022-08-17","conditions":"Multiple Myeloma","enrollment":317},{"nctId":"NCT05704049","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-04-05","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":118},{"nctId":"NCT04653246","phase":"PHASE2","title":"Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jacob Laubach, MD","startDate":"2021-07-13","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant","enrollment":52},{"nctId":"NCT04850599","phase":"PHASE2","title":"Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2022-06-14","conditions":"Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma","enrollment":5},{"nctId":"NCT04270409","phase":"PHASE3","title":"Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2020-06-16","conditions":"Plasma Cell Myeloma","enrollment":337},{"nctId":"NCT05405166","phase":"PHASE3","title":"SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2022-06-23","conditions":"Plasma Cell Myeloma Recurrent","enrollment":531},{"nctId":"NCT02960555","phase":"PHASE2","title":"Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-02-08","conditions":"Smoldering Plasma Cell Myeloma","enrollment":61},{"nctId":"NCT03769181","phase":"PHASE1, PHASE2","title":"A Study of Isatuximab-based Therapy in Participants With Lymphoma","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-12-11","conditions":"Lymphoma","enrollment":58},{"nctId":"NCT04294459","phase":"PHASE1, PHASE2","title":"Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation","status":"TERMINATED","sponsor":"Sanofi","startDate":"2020-06-18","conditions":"Immune System Disorder","enrollment":23},{"nctId":"NCT04045795","phase":"PHASE1","title":"Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-08-06","conditions":"Multiple Myeloma","enrollment":56},{"nctId":"NCT03499808","phase":"PHASE2","title":"S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2018-06-06","conditions":"Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea","enrollment":43},{"nctId":"NCT04643002","phase":"PHASE1, PHASE2","title":"Isatuximab in Combination With Novel Agents in RRMM - Master Protocol","status":"RECRUITING","sponsor":"Sanofi","startDate":"2021-01-25","conditions":"Plasma Cell Myeloma Refractory","enrollment":258},{"nctId":"NCT07045909","phase":"PHASE2","title":"Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)","status":"RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2025-06-30","conditions":"De Novo Multiple Myeloma, Anitocabtagene Autoleucel","enrollment":30},{"nctId":"NCT05123131","phase":"PHASE2","title":"Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cancer Trials Ireland","startDate":"2022-04-01","conditions":"Multiple Myeloma","enrollment":54},{"nctId":"NCT05346809","phase":"PHASE2","title":"Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma","status":"RECRUITING","sponsor":"Divaya Bhutani","startDate":"2023-03-31","conditions":"Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma","enrollment":39},{"nctId":"NCT04614558","phase":"PHASE2","title":"Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance","status":"RECRUITING","sponsor":"Columbia University","startDate":"2021-06-08","conditions":"Monoclonal Gammopathy","enrollment":27},{"nctId":"NCT02332850","phase":"PHASE1","title":"Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Martin, MD","startDate":"2015-01-21","conditions":"Multiple Myeloma","enrollment":83},{"nctId":"NCT04939844","phase":"PHASE2","title":"REST - Replacing Steroids in the Transplant Ineligble","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2021-06-29","conditions":"Multiple Myeloma","enrollment":51},{"nctId":"NCT04483739","phase":"PHASE3","title":"Isa-KRd vs KRd in Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Stem Cell Transplantation (IsKia TRIAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"European Myeloma Network B.V.","startDate":"2020-09-25","conditions":"Multiple Myeloma","enrollment":302},{"nctId":"NCT04965155","phase":"PHASE2","title":"A Trial for Relapsed Multiple Myeloma Patients (Isatuximab-dexamethasone)","status":"ACTIVE_NOT_RECRUITING","sponsor":"EMN Trial Office S.r.l. Impresa Sociale","startDate":"2021-03-21","conditions":"Relapsed Multiple Myeloma","enrollment":50},{"nctId":"NCT05669989","phase":"PHASE2","title":"International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-04-05","conditions":"Plasma Cell Myeloma","enrollment":70},{"nctId":"NCT02990338","phase":"PHASE3","title":"Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide and Dexamethasone in Refractory or Relapsed and Refractory Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-12-22","conditions":"Plasma Cell Myeloma","enrollment":307},{"nctId":"NCT06115135","phase":"PHASE2","title":"A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Oncotherapeutics","startDate":"2024-06-20","conditions":"Multiple Myeloma in Relapse, Multiple Myeloma, Refractory","enrollment":39},{"nctId":"NCT03319667","phase":"PHASE3","title":"A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2017-12-07","conditions":"Plasma Cell Myeloma","enrollment":475},{"nctId":"NCT01084252","phase":"PHASE1, PHASE2","title":"Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-05-11","conditions":"Hematological Malignancy","enrollment":351},{"nctId":"NCT04943302","phase":"PHASE2","title":"Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis","status":"WITHDRAWN","sponsor":"Tufts Medical Center","startDate":"2022-09-01","conditions":"Amyloidosis, Light Chain (AL) Amyloidosis","enrollment":""},{"nctId":"NCT03530683","phase":"PHASE1","title":"A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-05-14","conditions":"Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia","enrollment":189},{"nctId":"NCT02812706","phase":"PHASE1, PHASE2","title":"Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-09-05","conditions":"Multiple Myeloma","enrollment":36},{"nctId":"NCT03555149","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2018-09-27","conditions":"Colorectal Cancer","enrollment":96},{"nctId":"NCT04558931","phase":"PHASE2","title":"Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2021-06-02","conditions":"Multiple Myeloma","enrollment":62},{"nctId":"NCT03637764","phase":"PHASE1, PHASE2","title":"Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"Sanofi","startDate":"2018-08-06","conditions":"Neoplasm","enrollment":107},{"nctId":"NCT04287855","phase":"PHASE2","title":"Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone With Carfilzomib in Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2020-08-28","conditions":"Multiple Myeloma in Relapse, Multiple Myeloma, Refractory","enrollment":82},{"nctId":"NCT05558319","phase":"PHASE3","title":"NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide","status":"NOT_YET_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2022-10","conditions":"Newly Diagnosed Multiple Myeloma","enrollment":480},{"nctId":"NCT04802031","phase":"PHASE2","title":"Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma","status":"WITHDRAWN","sponsor":"Thomas Martin, MD","startDate":"2021-05-28","conditions":"Relapsed Multiple Myeloma, Refractory Multiple Myeloma","enrollment":""},{"nctId":"NCT05147493","phase":"PHASE2","title":"A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment","status":"UNKNOWN","sponsor":"Hellenic Society of Hematology","startDate":"2022-04","conditions":"Multiple Myeloma, Renal Impairment, Neoplasms, Plasma Cell","enrollment":51},{"nctId":"NCT05298683","phase":"PHASE2","title":"A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor","status":"UNKNOWN","sponsor":"Hellenic Society of Hematology","startDate":"2022-05","conditions":"Multiple Myeloma, Renal Impairment, Neoplasms, Plasma Cell","enrollment":108},{"nctId":"NCT02999633","phase":"PHASE2","title":"Safety and Efficacy of Isatuximab in Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"Sanofi","startDate":"2017-03-08","conditions":"T-cell Type Acute Leukemia-Precursor, T-lymphoblastic Lymphoma/Leukaemia","enrollment":14},{"nctId":"NCT04763616","phase":"PHASE2","title":"Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy","status":"RECRUITING","sponsor":"Won Seog Kim","startDate":"2021-06-25","conditions":"Natural Killer/T-cell Lymphoma, Relapsed Natural Killer/T-cell Lymphoma, Refractory Natural Killer/T-cell Lymphoma","enrollment":37}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["SAR650984","SARCLISA®"],"phase":"phase_3","status":"active","brandName":"Isatuximab IV","genericName":"Isatuximab IV","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Isatuximab IV is used to treat multiple myeloma, including relapse, refractory, and newly diagnosed cases with severe renal impairment. It is administered intravenously as part of a combination therapy, such as with CM336, a BCMA/CD3 bispecific antibody.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}